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Prostate cancer is one of the most 
commonly diagnosed forms of cancer 
in males; it is the second most frequent 
cause of cancer related death in the United 
States. A diagnosis of a malignant tumor 
is divided into four stages. During stage 
one, the cancer cells remains localized 
within the tumor itself. As the tumor 
grow and progress into stage two, cells 
break through the basement membrane 
guarding the surrounding tissue, and in 
stage three they migrated to the nearest 
lymph nodes. Once the cancer has 
invaded the lymph nodes then it has 
free access to the bloodstream, and the 
prognosis significantly diminishes. Cancer 
is deadliest during stage 4 because at 
this stage, cancerous cells can be found 
throughout the body system, making it 
nearly impossible to combat. Stages 1-3 
is also considered a primary stage, and 
during this stage the cancer is confined  to 
the  prostate gland only, so it is treatable. 
In the metastatic stage, the cancer spreads 
beyond the prostate which increases the 
mortality rate. 
One factor that has been identified that 
leads to metastasis is the activation of 
the c-Met signalling pathway. The c-Met 
signalling pathway has been implicated in 
many functions including metastasis. The 
only known ligand of the c-Met receptor 
is hepatocyte growth receptor (HGF). 
HGF has been shown to promote the 
invasiveness of cancer cells by increasing 
matrix adhesion, which encourages the 
migration of tumor cells from the point of 
origination as well as secretion of cancer 
specific enzymes that allow the cancer cells 
to break through the basement membrane. 
Previous studies have shown CD82 to be 
an active metastasis suppressor in normal, 
healthy cells. What is not known is how 
the loss of CD82 in cancer cells enables 
them to metastasize beyond their original 
tissue. CD82 is a known metastasize 
tumor suppressor in prostate cancer and it 
was first identified by Dong et.al. Previous 
rat studies have shown that CD82 
prevents metastasis but does not affect 
tumor formation. In a normal cell CD82 
is highly expressed especially in the spleen, 
thymus, prostate, lungs, kidneys and other 
vital organs. However, in a cancerous cell 
CD82 is under-expressed and down-
regulated which allows the tumor to 
progress. Loss or low expression of CD82 
has been observed in many invasive and 
metastatic tumors, which means loss 
of CD82 is correlated with changes in 
cytoskeleton structure of the cells. Some 
of the changes may allow cells to move 
freely (no longer adhering) and be invasive 
as well as help with cell migration. The 
proposed research looked into how the 
reintroduction of CD82 in metastatic 
prostate cancer would prevent cell motility 
and affect cell signalling and cell adhesion. 
Understanding the mechanism by which 
re-introduction of CD82 affect cell 
signalling, cell adhesion and cytoskeleton 
structure rearrangement propose a greater 
potential for controlling the mechanism 
of metastasis. If metastasis could be 
controlled, it would provide a huge step 
towards preventing metastatic cancer.
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